At-home care for breast cancer patients using an e-health app
At-home Breast Oncology Care Delivered With E-health Solutions The ABODE Study
This study is testing whether using a special app for breast cancer patients, along with their regular care, can help them feel more involved in their treatment compared to just receiving standard care alone.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | University Health Network, Toronto Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT05989477 on ClinicalTrials.gov |
What this trial studies
This study evaluates a multi-dimensional remote eHealth solution designed for newly diagnosed breast cancer patients. Participants will be randomly assigned to either use a Breast Cancer Treatment Application (app) alongside standard care or receive standard care alone. The app facilitates virtual consultations, provides educational materials, and collects patient-reported outcome measures (PROMs). The primary objective is to assess changes in patient activation over one year, while secondary outcomes will include additional PROMs and data from wearable devices.
Who should consider this trial
Good fit: Ideal candidates are females aged 18 and older, diagnosed with primary invasive breast cancer who will undergo surgery as their first treatment step.
Not a fit: Patients with non-operable or metastatic breast cancer, or those with significant hearing or visual challenges, may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance patient engagement and self-management in breast cancer care.
How similar studies have performed: Other studies have shown promise in using e-health solutions for patient engagement, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Females (assigned female at birth)\* * Diagnosed with first, primary invasive BC * Must have surgery as their first step in treatment pathway * Age≥18 * Access to an electronic device with connection to the internet * A valid email address * Can communicate in English \*Since BC risk is sex-related and based on physiological values, our inclusion criteria are based on sex (not gender) Exclusion criteria: * Males (assigned male at birth), as BC surgical treatment options and experiences are different * Diagnosed with non-operable breast cancer * Stage 4/metastatic (whether determined at diagnosis or during surgery) * Those with hearing or visual challenges * Neo-adjuvant chemotherapy * Should not be enrolled in any other UHN study using an e-Health application * Breast cancer surgery is scheduled for less 5 business days after enrollment
Where this trial is running
Toronto, Ontario
- Tulin Cil — Toronto, Ontario, Canada (Recruiting)
Study contacts
- Principal investigator: Tulin Cil, MD, MEd — University Health Network, Toronto
- Study coordinator: Tulin Cil, MD, MEd
- Email: tulin.cil@uhn.ca
- Phone: 416-946-4507
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.